Caption Management’s Regenxbio RGNX Stock Holding History

Caption Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,000	Closed	-$432K	–	1977
2025 Q4	$432K	Hold	30,000	–	–	﹤0.01%	1265
2025 Q3	$290K	Hold	30,000	–	–	﹤0.01%	1409
2025 Q2	$246K	Hold	30,000	–	–	﹤0.01%	1229
2025 Q1	$215K	Buy	+30,000	New	+$223K	﹤0.01%	1262
2024 Q3	–	Sell	-15,500	Closed	-$181K	–	1546
2024 Q2	$181K	Sell	15,500 -4,500	-23%	-$70K	﹤0.01%	963
2024 Q1	$421K	Sell	20,000 -25,000	-56%	-$445K	0.01%	908
2023 Q4	$808K	Buy	+45,000	New	+$793K	0.01%	854
2023 Q2	–	Sell	-27,000	Closed	-$511K	–	1353
2023 Q1	$511K	Hold	27,000	–	–	0.01%	788
2022 Q4	$612K	Sell	27,000 -3,000	-10%	-$67.8K	0.01%	873
2022 Q3	$794K	Hold	30,000	–	–	0.01%	940
2022 Q2	$741K	Buy	+30,000	New	+$749K	0.01%	980
2022 Q1	–	Sell	-30,000	Closed	-$981K	–	1863
2021 Q4	$981K	Hold	30,000	–	–	0.01%	1057
2021 Q3	$1.26M	Hold	30,000	–	–	0.01%	952
2021 Q2	$1.17M	Buy	30,000 +15,000	+100%	+$536K	0.02%	847
2021 Q1	$512K	Sell	15,000 -15,000	-50%	-$640K	0.01%	797
2020 Q4	$1.36M	Sell	30,000 -15,000	-33%	-$524K	0.03%	540
2020 Q3	$1.24M	Buy	+45,000	New	+$1.47M	0.03%	566

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's RGNX Position: Q4 2025 in Review

Caption Management sold out of Regenxbio (RGNX) in Q4 2025, closing a stake of 4,123 shares — an estimated $51.4K sold.

Caption Management first reported a position in RGNX in Q3 2020 and held it in 8 quarters. The position peaked at $289K in Q3 2020. 174 funds tracked by Wall St. Rank hold RGNX as of Q4 2025.

Caption Management reported no remaining Regenxbio position as of Q4 2025 after selling out during the quarter.
Caption Management sold 4,123 Regenxbio shares in Q4 2025, an estimated $51.4K.
Caption Management first reported a position in Regenxbio in Q3 2020 and held it in 8 quarters.
Caption Management's Regenxbio position peaked at $289K in Q3 2020.
174 funds tracked by Wall St. Rank held Regenxbio as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.